Kos Gets GMP Warning Letter On Niaspan, Advicor Production
The quality control unit failed to investigate dissolution and content uniformity failures for the lipid-altering products, FDA says. The company was cited for similar violations in 2002.
The quality control unit failed to investigate dissolution and content uniformity failures for the lipid-altering products, FDA says. The company was cited for similar violations in 2002.